Abstract
BackgroundThe relative new subspecialty ‘cardio-oncology’ was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy–related cardiovascular adverse events. In recent years, specialised cardio-oncology services have been implemented worldwide, which all strive to improve the cardiovascular health of cancer patients. However, limited data are currently available on the outcomes and experiences of these specialised services, and optimal strategies for cardio-oncological care have not been established.AimThe ONCOR registry has been created for prospective data collection and evaluation of cardio-oncological care in daily practice.MethodsDutch hospitals using a standardised cardio-oncology care pathway are included in this national, multicentre, observational cohort study. All patients visiting these cardio-oncology services are eligible for study inclusion. Data collection at baseline consists of the (planned) cancer treatment and the cardiovascular risk profile, which are used to estimate the cardiotoxic risk. Information regarding invasive and noninvasive tests is collected during the time patients receive cardio-oncological care. Outcome data consist of the incidence of cardiovascular complications and major adverse cardiac events, and the impact of these events on the oncological treatment.DiscussionOutcomes of the ONCOR registry may aid in gaining more insight into the incidence of cancer therapy–related cardiovascular complications. The registry facilitates research on mechanisms of cardiovascular complications and on diagnostic, prognostic and therapeutic strategies. In addition, it provides a platform for future (interventional) studies. Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate.Electronic supplementary materialThe online version of this article (10.1007/s12471-020-01517-8) contains supplementary material, which is available to authorized users.
Highlights
Improvements in the early detection and treatment of cancer over the last decades have led to increasing numbers of cancer survivors worldwide [1, 2]
Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate
The overarching aim of this subspecialty is the optimisation of cardiovascular health of cancer patients with pre-existent cardiovascular disease to enable the initiation of the antineoplastic treatment with the most optimal benefit-risk ratio, to improve cancer treatment tolerability, and to manage and to prevent cardiovascular complications
Summary
Improvements in the early detection and treatment of cancer over the last decades have led to increasing numbers of cancer survivors worldwide [1, 2]. The prognosis of patients treated in a palliative setting continues to improve and several malignancies are evolving into chronic conditions. With these advances, the prevention and management of short- and long-term treatment-related side effects are gaining importance. With the growing awareness of these complications among healthcare professionals treating cancer patients and survivors and a demand for an interdisciplinary approach to the management of cancer therapy–related cardiovascular adverse events, a new discipline termed ‘cardio-oncology’ has emerged in the late ’90s [7]. The relative new subspecialty ‘cardiooncology’ was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy–related cardiovascular adverse events. Aim The ONCOR registry has been created for prospective data collection and evaluation of cardiooncological care in daily practice
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
